IDS, a leading producer of diagnostic testing kits, announces a collaboration with Dr. Martin Bidlingmaier to develop 5 major products for the new IDS 3×3® automated analyser.
Dr. Bidlingmaier, a world leader in Growth metabolism, is a member of the Endocrine Society and Growth Hormone Research Society and is also chair of the working group on growth hormone of the International Federation of Clinical Chemistry (IFCC).
Together with Prof. Christian Strasburger and Dr. Zida Wu, Dr Bidlingmaier has successfully developed tests to detect the abuse of growth hormone (HGH) in athletes which by decision of the World Anti-Doping Agency (WADA) was applied during the previous Olympic games in Athens and Torino.
Dr. Bidlingmaier will employ his skills to automate and commercialise existing unique manual world leading diagnostic assays in the fields of Growth and Hypertension within 1 year, to complete disease panels for the IDS automated 3×3® laboratory analyser. The new assays in Growth disorders include; Human Growth Hormone (HGH); Insulin Growth Factor (IGF-1); Insulin Growth Factor Binding Protein (IGFBP-3) and in Hypertension; Renin and Aldosterone. We believe the world market for these 5 products to be €50 million.
We expect to launch all 5 assays on the IDS 3×3® automated analyser in 2009.
A panel of diagnostic tests in the clinical field of Growth will be of particular use to the Clinical and Pharmaceutical markets. New indications and new therapies for Growth disorders and the approval of several new drugs have revitalised the diagnostic market for the panel of growth assays, HGH, IGF-I and IGFBP-3. These assays aid in the assessment of the right diagnosis and ensure correct dosing for individuals with Growth related disorders.
The additional tests that Dr Bidlingmaier will develop (Renin and Aldosterone) have clinical use for the detection and monitoring of patients with Hypertension. The renin-angiotensin system (RAS) or the renin-angiotensin-aldosterone system (RAAS) is a hormone system that helps regulate long-term blood pressure and the need to monitor this system is of prime importance. Many patients with Hypertension are prescribed drugs called hypertensives and need to be monitored continuously with tests for Renin and Aldosterone.
The market for hypertensives – led by the angiotensin II antagonists – is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic with a prediction that worldwide there will be more than 1.5 billion sufferers of this disease by 2025.
Dr Bidlingmaier said:
With the development of these new assays we are focusing on improving the specificity and accuracy of the diagnostic testing. This will give the diagnostic laboratories and pharmaceutical companies new applications and more reliable tools for monitoring patients under treatment.
Tony Wilks, Sales & Marketing Director at IDS, commented:
Dr Bidlingmaiers reputation and academic knowledge are immensely valuable to IDS future strategy of automation, especially in the expanding and highly lucrative markets of Growth Disorders and Hypertension. We believe his reputation with key researchers worldwide, especially within the clinical pharmaceutical industry and academia, will further enhance our international profile and positively impact sales.
Immunodiagnostic Systems Holdings plc
Parkgreen Communications Ltd
Paul Hailes, Finance Director
Tel: 0191 519 0660
Tel: 020 7479 7933
Mob: 07900 346 978
Oriel Securities Limited
Tel: 020 7710 7600
Dr. Bidlingmaier is Head of the Endocrine Research Laboratories at the Medizinische Klinik – Innenstadt (Medical Department), Klinikum der Universität, Ludwig-Maximilians University, Munich, Germany. He graduated from medical School in 1993, received training in internal medicine at the Red-Cross Hospital, Munich, in basic sciences and clinical chemistry at the Neuroendocrine and Clinical Laboratories at the Medizinische Klinik – Innenstadt, and in microbiology at the Max-von-Pettenkofer Institute, Ludwig-Maximilians University, Munich, Germany.
He received his medical education with a main focus on Endocrinology under Professor Christian Strasburger, one of the leading opinion leaders in the field of Growth Research. His main clinical and research interest is pathophysiology and biochemistry of pituitary and adrenal diseases. His Endocrine Research Laboratory serves many multi-central clinical studies for the pharmaceutical industry.
Dr. Bidlingmaier has eminent experience in the development of specific antibodies for immunoassays and the development of immunoassays in the field of growth and hypertension.